Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Operating expenses:
Research and development	$ 7,698	$ 3,788	$ 24,673	$ 9,859
General and administrative	4,688	4,110	14,540	10,992
Acquired in-process research and development				164,617
Total operating expenses	12,386	7,898	39,213	185,468
Loss from operations	(12,386)	(7,898)	(39,213)	(185,468)
Other income (expense):
Interest and investment income	437	35	706	89
Other expense, net	(48)	(8)	(64)	(42)
Total other income, net	389	27	642	47
Net loss	(11,997)	(7,871)	(38,571)	(185,421)
Dividend on convertible preferred stock related to beneficial conversion feature and issuance costs				(24,437)
Net loss attributable to common shareholders	$ (11,997)	$ (7,871)	$ (38,571)	$ (209,858)
Net loss per share - basic	$ (0.87)	$ (0.61)	$ (2.91)	$ (27.81)
Net loss per share - diluted	$ (0.87)	$ (0.61)	$ (2.91)	$ (27.81)
Weighted-average common shares outstanding used in net loss per share - basic	13,742,385	12,830,782	13,261,422	7,546,969
Weighted-average common shares outstanding used in net loss per share - diluted	13,742,385	12,830,782	13,261,422	7,546,969